These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36085259)

  • 1. Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors.
    Zhang S; Rao G; Heimberger A; Li S
    Cytokine Growth Factor Rev; 2023 Feb; 69():73-79. PubMed ID: 36085259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.
    Latha K; Yan J; Yang Y; Gressot LV; Kong LY; Manyam G; Ezhilarasan R; Wang Q; Sulman EP; Eric Davis R; Huang S; Fuller GN; Rao A; Heimberger AB; Li S; Rao G
    J Natl Cancer Inst; 2019 Mar; 111(3):292-300. PubMed ID: 29947810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
    Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGL2 promotes tumor progression in the CNS by suppressing CD103
    Yan J; Zhao Q; Gabrusiewicz K; Kong LY; Xia X; Wang J; Ott M; Xu J; Davis RE; Huo L; Rao G; Sun SC; Watowich SS; Heimberger AB; Li S
    Nat Commun; 2019 Jan; 10(1):448. PubMed ID: 30683885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4+ CD25+ Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice.
    Wang J; Vuitton DA; Müller N; Hemphill A; Spiliotis M; Blagosklonov O; Grandgirard D; Leib SL; Shalev I; Levy G; Lu X; Lin R; Wen H; Gottstein B
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003755. PubMed ID: 25955764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the Fibrinogen-Like Protein 2:FcγRIIB/RIII immunosuppressive pathway enhances antiviral T-cell and B-cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13.
    Luft O; Khattar R; Farrokhi K; Ferri D; Yavorska N; Zhang J; Sadozai H; Adeyi O; Chruscinski A; Levy GA; Selzner N
    Immunology; 2018 Jul; 154(3):476-489. PubMed ID: 29341118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models.
    Galpin KJC; Rodriguez GM; Maranda V; Cook DP; Macdonald E; Murshed H; Zhao S; McCloskey CW; Chruscinski A; Levy GA; Ardolino M; Vanderhyden BC
    Sci Rep; 2024 Jan; 14(1):787. PubMed ID: 38191799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
    Song Z; Wang Y; Du Y; Zhang Z; Yuan Y
    Int Immunopharmacol; 2020 Nov; 88():106894. PubMed ID: 32858440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts.
    Urbanellis P; Shyu W; Khattar R; Wang J; Zakharova A; He W; Sadozai H; Amir AZ; Shalev I; Phillips MJ; Adeyi O; Ross H; Grant D; Levy GA; Chruscinski A
    Immunology; 2015 Jan; 144(1):91-106. PubMed ID: 24990517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A homozygous truncating mutation of FGL2 is associated with immune dysregulation.
    Janssen E; Alosaimi MF; Alazami AM; Alsuliman A; Alaiya A; Al-Saud B; Al-Mousa H; Al-Zaid TJ; Smith E; Platt CD; Alruwaili H; Albanyan S; Al-Mayouf SM; Geha RS
    J Allergy Clin Immunol; 2023 Feb; 151(2):572-578.e1. PubMed ID: 36243222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.
    Hu J; Yan J; Rao G; Latha K; Overwijk WW; Heimberger AB; Li S
    Int Rev Immunol; 2016 Jul; 35(4):325-339. PubMed ID: 25259408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer.
    Zhu Y; Zhang L; Zha H; Yang F; Hu C; Chen L; Guo B; Zhu B
    Int J Biol Sci; 2017; 13(6):804-814. PubMed ID: 28656005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE.
    Khattar R; Luft O; Yavorska N; Shalev I; Phillips MJ; Adeyi O; Gao D; Bartczak A; Urbanellis P; Shyu W; Zhang J; Manuel J; Levy GA; Selzner N
    PLoS One; 2013; 8(10):e72309. PubMed ID: 24146739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting FGL2 in glioma immunosuppression and malignant progression.
    Ma X; Zhu H; Cheng L; Chen X; Shu K; Zhang S
    Front Oncol; 2022; 12():1004700. PubMed ID: 36313679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clara Cell 10 kDa Protein Alleviates Murine Hepatitis Virus Strain 3-Induced Fulminant Hepatitis by Inhibiting Fibrinogen-Like Protein 2 Expression.
    Yu H; Liu Y; Wang H; Wan X; Huang J; Yan W; Xi D; Luo X; Shen G; Ning Q
    Front Immunol; 2018; 9():2935. PubMed ID: 30619295
    [No Abstract]   [Full Text] [Related]  

  • 16. FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells.
    Yan J; Zhao Q; Wang J; Tian X; Wang J; Xia X; Ott M; Rao G; Heimberger AB; Li S
    Cancer Lett; 2021 May; 506():83-94. PubMed ID: 33676940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated macrophage polarization promotes the progression of esophageal carcinoma.
    Yuan X; Li Y; Zhang AZ; Jiang CH; Li FP; Xie YF; Li JF; Liang WH; Zhang HJ; Liu CX; Pang LJ; Shen XH; Li F; Hu JM
    Aging (Albany NY); 2020 Dec; 13(2):2049-2072. PubMed ID: 33323552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells.
    Chan CW; Kay LS; Khadaroo RG; Chan MW; Lakatoo S; Young KJ; Zhang L; Gorczynski RM; Cattral M; Rotstein O; Levy GA
    J Immunol; 2003 Apr; 170(8):4036-44. PubMed ID: 12682232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen-Like Protein 2 (FGL2) is a Novel Biomarker for Clinical Prediction of Human Breast Cancer.
    Feng Y; Guo C; Wang H; Zhao L; Wang W; Wang T; Feng Y; Yuan K; Huang G
    Med Sci Monit; 2020 Jul; 26():e923531. PubMed ID: 32716910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis.
    Shalev I; Liu H; Koscik C; Bartczak A; Javadi M; Wong KM; Maknojia A; He W; Liu MF; Diao J; Winter E; Manuel J; McCarthy D; Cattral M; Gommerman J; Clark DA; Phillips MJ; Gorczynski RR; Zhang L; Downey G; Grant D; Cybulsky MI; Levy G
    J Immunol; 2008 Jan; 180(1):249-60. PubMed ID: 18097026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.